Seven Bridges Part of the Blood Profiling Atlas Project to Help Fight CancerBY the_author();?> ON October 18
Earlier this year, the White House announced it launched an initiative that aims to boost the access of cancer-diagnosed patients to timely treatment. By accomplishing a handful of tasks, including “understanding of cancer and its prevention, early detection, treatment, and cure, new research, data, and computational capability, development of cancer treatments, [removal of] unnecessary regulatory barriers and optimal investment of federal resources”, the initiative ultimately seeks to end cancer as we know it.
Named Cancer Moonshot, the project set up a special task force – with the aim to manage investments, targeted incentives, private sector efforts, and patient initiatives, towards achieving the Cancer Moonshot milestones.
During the yesterday’s presentation of the task force’s report, the White House announced launching of the Blood Profiling Atlas project. The Atlas is collaboration between 20 stakeholders, which will work to create “an open database for liquid biopsies to potentially accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit”.
Among the participants is the Serbian-American Seven Bridges Genomics, whose biomedical data analysis platform will be used in the project. According to the report, Seven Bridges is going “to develop the Blood Profiling Atlas Analysis Cloud, which will suit the needs of the liquid biopsy community. It will also partner with the University of Chicago to ensure interoperability between its analytic platform and the Blood Profiling Atlas Data Commons, allowing molecular, clinical and imaging data to be easily, securely, and cost effectively analyzed by researchers across disciplines.”
In its press release, Seven Bridges said it will also join in with six months of engineering, bioinformatics and project management resources, as well as up to $500,000 in compute and storage resources to the project.
The project could be a huge step forward in that it would allow blood tests to replace invasive tissue biopsy, and create room for refined treatment, diagnosis and detection of cancer. But the complexity of the task and agreement on the most efficient use of voluminous sets of data requires cooperation between major stakeholders. The Blood Profiling Atlas project – that could make a decade of progress in the field in just five years possible – might be the crucial step that will bring key stakeholder to the table.